<SEC-DOCUMENT>0001140361-25-029350.txt : 20250807
<SEC-HEADER>0001140361-25-029350.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807074052
ACCESSION NUMBER:		0001140361-25-029350
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250807
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		251191652

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20053240_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:imcr="http://immunocore.com./20250807" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Disclosure
         Document created using Broadridge PROfile 25.7.1.5324
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_b3355e7afd134da98ef2d366017b2bdd" contextRef="c20250807to20250807" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_2bb2ff8a1d514e0f92155a8af4dd2855" contextRef="c20250807to20250807">0001671927</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_ac7c4eab29c54bb6b88e909e2360e22b" contextRef="c20250807to20250807">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:Security12bTitle" id="Fact_d07e454d9f4444e1ad37e53e75c19776" contextRef="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember">Ordinary share, nominal value 0.002 per share*</ix:nonNumeric><ix:nonNumeric name="dei:Security12bTitle" id="Fact_5af8aa2b527b407485ad42ded70d51ee" contextRef="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember">American Depositary Shares, each representing one ordinary share, nominal value 0.002 per share</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="imcr-20250807.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250807to20250807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-07</xbrli:startDate><xbrli:endDate>2025-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imcr:OrdinaryShareNominalValue0002PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-07</xbrli:startDate><xbrli:endDate>2025-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-07</xbrli:startDate><xbrli:endDate>2025-08-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

  <div><span style="font-size: 10pt;"><br/>
  </span></div>

  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_e14cb2c6bd1f4d33a1db6fca8b703a2d" contextRef="c20250807to20250807">8-K</ix:nonNumeric></div>

  <div><span style="font-size: 10pt;"><br/>
  </span></div>

  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_dceaf50e2d524f0fae6e5b59b7205fc4" contextRef="c20250807to20250807" format="ixt:date-monthname-day-year-en">August 7, 2025</ix:nonNumeric></div>

  <div><span style="font-size: 10pt;"><br/>
  </span></div>

  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_e55dc27569a8495e97786f825e9188e2" contextRef="c20250807to20250807">Immunocore Holdings plc</ix:nonNumeric><br/>
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its Charter)</div>

  <div><span style="font-size: 10pt;"><br/>
  </span></div>

  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
  <div style="font-size: 10pt;"><br/>
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_06998ea623be432aad71bf315b91f67d" contextRef="c20250807to20250807" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric></span><br/>
          </div>
        </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_7dce5ffc0f264b20abdca32b4a45a20f" contextRef="c20250807to20250807">001-39992</ix:nonNumeric></span><br/>
          </div>
        </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><span style="-sec-ix-hidden:Fact_ac7c4eab29c54bb6b88e909e2360e22b">Not Applicable</span></span><br/>
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
        </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(Commission File Number)</div>
        </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(IRS Employer Identification No.)</div>
        </td>

  </tr>


</table>
  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 66%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_46e5c566e8eb405abf21725748935d1d" contextRef="c20250807to20250807">92 Park Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_95f617049bc942d593fd1b5f13a61778" contextRef="c20250807to20250807">Milton Park</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" id="Fact_2b35e479375a46ef8796d244fc39beff" contextRef="c20250807to20250807">Abingdon</ix:nonNumeric>,</div>
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_bfeab88c8d1646f09d58409c722f187c" contextRef="c20250807to20250807">Oxfordshire</ix:nonNumeric>,</div>
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_08740d26ec02473fa7b3e6b37c070ddd" contextRef="c20250807to20250807" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br/>
          </div>
        </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: bottom; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_4721703b195b4a7a98652eb8f2ba63f2" contextRef="c20250807to20250807">OX14 4RY</ix:nonNumeric><br/>
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 66%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(Address of principal executive offices)</div>
        </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(Zip Code)</div>
        </td>

  </tr>


</table>
  <div> <br/>
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">+<ix:nonNumeric name="dei:CityAreaCode" id="Fact_5fea8556eec74b66a8d562928004531a" contextRef="c20250807to20250807">44</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_957c021778bb4b7a964ddb527ceab834" contextRef="c20250807to20250807">1235 438600</ix:nonNumeric></div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former name or former address, if changed since last report)</div>

  <div><span style="font-size: 10pt;"><br/>
  </span></div>

  <div style="font-size: 10pt;">
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

  <div style="font-size: 10pt;"><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_15bef933971a4270a276eed798d5ad16" contextRef="c20250807to20250807" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
        </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
          <div style="font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
        </td>

  </tr>


</table>
  <div style="font-size: 10pt;"><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_39c6a35b10dc4b4db335ad40aa4e993f" contextRef="c20250807to20250807" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
        </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
          <div style="font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
        </td>

  </tr>


</table>
  <div style="font-size: 10pt;"><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_d1f93730d23d4d84931c37f4ffb1482b" contextRef="c20250807to20250807" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
        </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
          <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
        </td>

  </tr>


</table>
  <div style="font-size: 10pt;"><br/>
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_64c319898d924379b11fc0078e2c2447" contextRef="c20250807to20250807" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
        </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
          <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
        </td>

  </tr>


</table>
  <div style="font-size: 10pt;"><br/>
  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

  <div style="font-size: 10pt;"><br/>
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 62.17%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Title of each class</div>
        </td>

    <td style="width: 9.15%; vertical-align: bottom; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading</div>
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Symbol(s)</div>
        </td>

    <td style="width: 28.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Name of each exchange on which registered</div>
        </td>

  </tr>

  <tr>

    <td style="width: 62.17%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_5af8aa2b527b407485ad42ded70d51ee">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share</span></div>
              </div>
            </div>
          </div>
        </td>

    <td style="width: 9.15%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_2f4aa51e7378452fb34d506535263427" contextRef="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember">IMCR</ix:nonNumeric></div>
              </div>
            </div>
          </div>
        </td>

    <td style="width: 28.69%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_1f406a9fd194457b83c718f7976016b3" contextRef="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div>
              </div>
            </div>
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 62.17%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_d07e454d9f4444e1ad37e53e75c19776">Ordinary share, nominal value &#163;0.002 per share*</span></div>
          </div>
        </td>

    <td style="width: 9.15%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_4441c2a305004faa95535fac876dd8b9" contextRef="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember">*</ix:nonNumeric></div>
        </td>

    <td style="width: 28.69%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_b0a2ac7baae34f33a1f9ecb102667551" contextRef="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div>
          </div>
        </td>

  </tr>


</table>
  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">* <span style="font-family: 'Times New Roman'; font-style: italic;">Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq
      Stock Market LLC.</span></div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of
    the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_d9646ea31d2f47d493701a56d2ced180" contextRef="c20250807to20250807" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
    accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: 'Times New Roman';">&#9744;</span></div>

  <div style="font-size: 10pt;"><br/>
  </div>

  <div style="text-align: left; font-size: 10pt;">
    <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 2.02.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
          <div style="font-family: 'Times New Roman'; font-weight: bold;">Results of Operations and Financial Condition.</div>
        </td>

  </tr>


</table>
  <div style="font-size: 10pt;"><br/>
  </div>

  <div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman'; font-size: 10pt;">On August<span style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</span>7, 2025, Immunocore Holdings plc (the &#8220;Company&#8221;) issued a press release
    announcing its financial results for the second quarter ended June 30, 2025, as well as other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.</div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman'; font-size: 10pt;">The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for
    purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company&#8217;s filings under the
    Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.</div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
          <div style="font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits</div>
        </td>

  </tr>


</table>
  <div style="font-size: 10pt;"><br/>
  </div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
        </td>

    <td style="width: 90%; vertical-align: bottom; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
        </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20053240_ex99-1.htm">99.1</a></div>
        </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Press Release dated August 7, 2025.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">104</div>
        </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
        </td>

  </tr>


</table>
  <div><br/>
  </div>

  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

  </div>

  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

  <div style="font-size: 10pt;"><br/>
  </div>

  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
    hereunto duly authorized.</div>

  <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
    </span></div>

  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 37.22%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td colspan="4" style="vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">IMMUNOCORE HOLDINGS PLC</div>
        </td>

  </tr>

  <tr>

    <td style="width: 37.22%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td colspan="3" style="vertical-align: middle; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 37.22%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Dated: August 7, 2025</div>
        </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
        </td>

    <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">/s/ Bahija Jallal, Ph.D.</div>
        </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 37.22%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 9%; vertical-align: bottom; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
        </td>

    <td style="width: 48%; vertical-align: bottom; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Bahija Jallal, Ph.D.</div>
        </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 37.22%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 9%; vertical-align: bottom; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
        </td>

    <td style="width: 48%; vertical-align: bottom; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Chief Executive Officer</div>
        </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

  </tr>


</table>
  <div style="font-size: 10pt;"><br/>
  </div>

  <div><br/></div>

  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20053240_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Disclosure
         Document created using Broadridge PROfile 25.7.1.5324
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;">Exhibit 99.1</font></div>
  <div style="text-align: right;"><font style="font-size: 10pt;"><br>
    </font></div>
  <div style="text-align: left;">
    <div><img src="image00002.jpg"></div>
    <br>
    <div style="text-align: center; margin-left: 3.3pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore reports second quarter financial results and provides a business update</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Cash, cash equivalents and marketable securities of $883 million as of June 30, 2025</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Conference call today, August 7 at 8:00 AM ET, 1:00 PM BST</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; GAITHERSBURG, Md., US</font>, August 7, 2025) <u>Immunocore

        Holdings plc (Nasdaq: IMCR) (&#8220;Immunocore&#8221; or the &#8220;Company&#8221;),</u> a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious
      diseases and autoimmune diseases, today announced its financial results for the second quarter ended June 30, 2025, and provided a business update.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;We are delighted to announce robust revenue for the first half of 2025, a 32% year-over-year increase. This is testament to our steadfast dedication to expanding access
      to KIMMTRAK in the US and across the globe,&#8221; said Bahija Jallal, Chief Executive Officer of Immunocore. &#8220;Our Phase 3 TEBE-AM trial remains on schedule to complete enrollment in the first half of 2026, and we are making good progress with our other
      two Phase 3 trials: PRISM-MEL-301 and ATOM. We are also advancing our Phase 1/2 trials in oncology and infectious diseases and preparing for the clinical trial applications for our autoimmune candidates, further underscoring the depth and diversity
      of our platform.&#8221;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Second Quarter 2025 Highlights (including post-period)</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>KIMMTRAK</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company&#8217;s lead product, KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (tebentafusp), is approved in 39 countries and has been launched in 28 countries globally to date
      for HLA-A*02:01 positive people with metastatic uveal melanoma (mUM). KIMMTRAK continues to be the standard of care in most markets where it is launched.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 1 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company sees three key growth areas as it plans to expand patient reach for KIMMTRAK, including continued global expansion in mUM, the potential
      expansion into 2L+ advanced cutaneous melanoma (CM), and the potential expansion into adjuvant uveal melanoma.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Metastatic uveal melanoma</div>
    <table cellspacing="0" cellpadding="0" id="zb5aa6c1384d44aa48c1d474bed636a73" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">KIMMTRAK net product sales were $98.0 million and $191.8 million for the three and six months ended June 30, 2025, respectively, representing increases of 30% and 32% respectively, as compared to the
              same periods in 2024.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zdaada1d866c44eb09d3c2aee9f801f8f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">15% year-over-year quarterly growth in the United States, with demand continuing to grow, duration of treatment extending, and the majority of patients treated in the community setting (70%).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z7d5cba2ad30d4acb891fbb181a2f32ea" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">71% year-over-year quarterly growth in Europe and in international regions combined, driven by increased demand, new country launches, and completion of price negotiations in France and Germany.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zd25d4e8e3ba84d218bce119b2e148b71" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company signed a distribution and commercialization agreement with Er-Kim Pharmaceuticals for KIMMTRAK, for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal
              melanoma, in Turkey, the Middle East, North Africa, Caucasus and the Commonwealth of Independent States regions.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">2L+ advanced cutaneous melanoma</div>
    <table cellspacing="0" cellpadding="0" id="zb1802c1dd0de4769bac89ccc2fc1aeba" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is currently enrolling patients in the TEBE-AM registrational Phase 3 trial and expects to complete enrollment in the first half of 2026.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z4d93b0f40cc54169923b10cb49a9940c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Phase 3 trial is enrolling three arms: tebentafusp monotherapy, tebentafusp in combination with pembrolizumab, and a control (investigator's choice of therapy including options such as
              investigator&#8217;s choice of clinical trials, chemotherapy, or retreatment with anti-PD1 or BRAF therapy). The primary endpoint of the randomized Phase 3 trial is Overall Survival (OS).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zb7c8b139a874480ea283534e93317ce9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">There is great unmet need in second- and later-line cutaneous melanoma, with no therapy having shown an OS improvement post checkpoint inhibitors in a randomized clinical trial. The Company estimates
              that there is a potential to address up to 4,000 previously treated advanced CM patients.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Adjuvant uveal (or ocular) melanoma</div>
    <table cellspacing="0" cellpadding="0" id="zc96c1e08f3124c9ca7cb8d65c6111b4e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The European Organisation for Research and Treatment of Cancer (EORTC) continues to expand the site footprint of the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z77ed77b1badd46a0802fc4606deac032" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company estimates that the HLA-A*02:01 high-risk adjuvant uveal melanoma patient population could be up to 1,200 patients in the US and Europe.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>PRAME portfolio</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Brenetafusp is the Company&#8217;s lead PRAME-A02 ImmTAC bispecific candidate. Brenetafusp is being evaluated in combination with nivolumab in a Phase 3
      registrational trial (PRISM-MEL-301) in patients with first-line, advanced cutaneous melanoma, and in a Phase 1/2 clinical trial as monotherapy and in combination across multiple tumor types, including ovarian cancer and non-small cell lung cancer
      (NSCLC).</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 2 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">PRISM-MEL-301 &#8211; First PRAME Phase 3 clinical trial with brenetafusp in first-line advanced cutaneous melanoma</div>
    <table cellspacing="0" cellpadding="0" id="zd2e97dd8b87844aa9791fc50236502d0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company has now activated over 150 clinical trial sites around the world, enrolling patients in the registrational Phase 3 clinical trial evaluating brenetafusp + nivolumab versus a control arm
              of either nivolumab or nivolumab + relatlimab for HLA-A*02:01 positive patients with first-line, advanced or metastatic cutaneous melanoma.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="ze769b6aa66f34112a20b49ee74bf9b8b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The trial is currently randomizing to three arms: two brenetafusp dose regimens (40 mcg and 160 mcg) and a control arm.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="za1eeae8ad46b49c5a1ae55931ce9a77a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">In a pre-planned analysis, the Independent Data Monitoring Committee (IDMC) reviewed the safety of the first 30 patients randomized and recommended to continue the study with no changes. The trial is
              on track for selection of the go-forward brenetafusp dose in the second half of 2025; this analysis will be conducted by an IDMC.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z6c449291470749f38f8827b0c4f5d919" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Despite approved therapies, there remains a need for improved progression-free survival and overall survival, and there is the potential to address an estimated 10,000 HLA-A*02:01 positive patients
              in the US and Europe.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1/2 clinical trial of brenetafusp in multiple solid tumors</div>
    <table cellspacing="0" cellpadding="0" id="z2556f6afadde4dff923611c5fce02dbc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company continues to evaluate brenetafusp in a Phase 1/2 trial in combination with non-platinum chemotherapies in platinum-resistant ovarian cancer (PROC) and with bevacizumab or with platinum
              chemotherapy in earlier lines of platinum-sensitive ovarian cancer (PSOC). In the same trial, the Company continues signal detection in metastatic non-small cell lung cancer (NSCLC) cohorts, including brenetafusp in combination with docetaxel
              and with osimertinib in earlier-line NSCLC.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z902e78ac332e460e8a6472869194193f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company estimates that, across all solid tumors, the annual number of eligible patients worldwide who test positive for HLA-A*02:01 is up to 150,000.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-P115C (PRAME-A02 Half-Life Extended) &amp; IMC-T119C (PRAME-A24)</div>
    <table cellspacing="0" cellpadding="0" id="z187a4baf7a0c4448a432e15cbc097fc7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is enrolling patients in the Phase 1 dose escalation trial, in multiple solid tumors, with IMC-P115C.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>IMC-R117C (PIWIL1) for colorectal and other gastrointestinal cancers</u></div>
    <table cellspacing="0" cellpadding="0" id="zd07f16047f6843c3bbe0a3eb7d6168c5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is enrolling patients in the Phase 1/2 dose escalation trial evaluating IMC-R117C in HLA-A*02:01 positive patients with advanced solid tumors, including colorectal cancer, as a single
              agent and in combination with standards of care.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>ImmTAV candidates for a functional cure in infectious diseases</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company&#8217;s bispecific TCR technology platform has the potential to offer a new approach for the treatment of certain chronic infections and aims
      to eliminate evidence of remaining virus in circulation after the patient stops taking medication - known as a &#8216;functional cure&#8217;. Two investigational candidates are in Phase 1 or Phase 1/2 trials for people living with human immunodeficiency virus
      (HIV) and people with chronic hepatitis B infection (HBV).</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 3 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1/2 trial of IMC-M113V (Gag-A02) for people living with HIV</div>
    <table cellspacing="0" cellpadding="0" id="z42cfc9802adf4fedb6d6a292401417dd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Patient enrollment continues at higher doses in the multiple ascending dose part of the Phase 1/2 clinical trial to identify a safe and tolerable dose.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1 trial of IMC-I109V (Envelope-A02) for people living with HBV or HBV-positive hepatocellular carcinoma</div>
    <table cellspacing="0" cellpadding="0" id="z0362db3e20b34af9b8bd77710ae49ae6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company will report data from the single ascending dose portion of the trial at the 2025 American Association for the Study of Liver Diseases&#8217; Meeting in November 2025.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Tissue-specific down modulation of the immune system for autoimmune diseases</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The key differentiator of the ImmTAAI platform is tissue-specific, down modulation of the immune system, as the candidates suppress pathogenic T
      cells via PD1 receptor agonism only when tethered to the target tissue.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-S118AI (PPI-A02) for type 1 diabetes</div>
    <table cellspacing="0" cellpadding="0" id="zaf5af0a9c0084752b5c3f67630c77411" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is on track to file a clinical trial application (CTA) or investigational new drug application (IND) for IMC-S118AI (PPI x PD1) in the second half of 2025.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-U120AI (CD1a) for atopic dermatitis as the initial indication - first universal program</div>
    <table cellspacing="0" cellpadding="0" id="z6033379112d8490b997dc1f39701a6f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company plans to file a CTA/IND for IMC-U120AI (CD1a x PD1) in 2026.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Corporate update</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On August 5, 2025, Rob Perez resigned as director of the Company, effective September 16, 2025. The Company expresses its appreciation to Mr. Perez for his dedication
      and service to Immunocore for the last 6 years.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Financial Results</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For the second quarter ended June 30, 2025, the Company generated net product sales of $98.0 million compared to $75.3 million for the same period in 2024. Sales of
      KIMMTRAK were $64.1 million in the United States, $33.0 million in Europe, and $0.8 million in the international regions. The increase in net product sales was due to increased volumes in the United States and Europe as well as global country
      expansion.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For the quarter ended June 30, 2025, research and development (R&amp;D) expenses were $69.0 million compared to $51.1 million for the same period in 2024. The increase
      was due to preclinical expenses related to the advancement of the Company&#8217;s autoimmune programs, including clinical material manufacturing for anticipated Phase 1 initiations, and clinical expenses related to the progression of the Company&#8217;s Phase 3
      trials, primarily TEBE-AM and PRISM-MEL-301.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For the quarter ended June 30, 2025, SG&amp;A expenses were $42.8 million compared to $38.6 million for the same period in 2024. The increase was primarily due to costs
      related to business support functions to support the Company&#8217;s growing pipeline and global commercial expansion.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 4 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Net loss for the quarter ended June 30, 2025, was $10.3 million, as compared to a net loss of $11.6 million for the same period in 2024. Basic and diluted loss per share
      was $0.20 for the quarter ended June 30, 2025, as compared to a basic and diluted loss per share of $0.23 for the same period in 2024.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cash, cash equivalents and marketable securities were $882.8 million as of June 30, 2025, as compared to $820.4 million as of December 31, 2024. The Company expects to
      pay, in the second half of 2025, approximately $65 million in sales-related rebate accruals.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">##</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About ImmTAC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> molecules for cancer</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore&#8217;s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against
      Cancer) molecules that are designed to redirect the immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these
      cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of
      mutational burden or immune infiltration, including immune &#8220;cold&#8221; low mutation rate tumors.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About ImmTAV molecules and infectious diseases</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">ImmTAV (Immune mobilising monoclonal TCRs Against Virus) molecules are novel bispecifics that are designed to enable the immune system to recognize and eliminate virally
      infected cells. Immunocore is advancing clinical candidates to cure patients with HIV and hepatitis B virus (HBV). The Company aims to achieve sustained control of HIV after patients stop anti-retroviral therapy (ART), without the risk of virological
      relapse or onward transmission. This is known as &#8216;functional cure&#8217;. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral antigens and markers of viral replication after stopping medication for people living with
      chronic HBV.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About ImmTAAI molecules and autoimmune diseases</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">ImmTAAI (Immune mobilizing monoclonal TCRs Against AutoImmune disease) molecules are novel bispecifics that are designed for tissue-specific down modulation of the
      immune system. When tethered to the tissue of interest, ImmTAAI candidates suppress pathogenic T cells via PD1 receptor agonism. The Company is currently advancing two candidates for autoimmune conditions, including Type 1 Diabetes and inflammatory
      dermatological diseases.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 5 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About PRISM-MEL301 (NCT06112314) &#8211; Phase 3 trial with brenetafusp (IMC-F106C, PRAME-A02) in 1L advanced cutaneous melanoma</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Phase 3 registrational trial is randomizing HLA-A*02:01-positive patients with previously untreated advanced melanoma to brenetafusp + nivolumab versus nivolumab or
      nivolumab + relatlimab, depending on the country where the patient is enrolled. The trial will initially randomize to three arms: two brenetafusp dose regimens (40 mcg and 160 mcg) and control arm. One of the two brenetafusp dose regimens will be
      discontinued after an initial review of the first 60 patients randomized to the two experimental arms (90 patients randomized total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review (BICR),
      with secondary endpoints of overall survival (OS) and overall response rate (ORR).</div>
    <div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About the IMC-F106C-101 Phase 1/2 trial</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumors including non-small cell lung and ovarian cancers. The Phase 1
      dose escalation trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C (brenetafusp), a bispecific protein built on Immunocore&#8217;s ImmTAC
      technology, and the Company&#8217;s first molecule to target the PRAME antigen. The Company is currently focusing on enrolling patients in combination arms with standards-of-care across multiple tumor types.</div>
    <div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About TEBE-AM - Phase 2/3 trial with tebentafusp (gp100xCD3) in second-line or later cutaneous melanoma</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The trial is randomizing patients with second-line or later advanced cutaneous melanoma who have progressed on an anti-PD1, received prior ipilimumab and, if applicable,
      received a BRAF kinase inhibitor. Patients are randomized to one of three arms including tebentafusp, as monotherapy or in combination with an anti-PD1, and a control arm. The primary endpoint is overall survival.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About the ATOM Phase 3 trial</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The EORTC-sponsored Phase 3 clinical trial will include sites in 10 EU countries and the United States and is randomizing HLA-A*02:01-positive patients with high-risk
      primary uveal melanoma after definitive treatment, by surgery or radiotherapy, and no evidence of metastatic disease on imaging. The trial is expected to enroll a total of 290 patients who will be randomized 1:1 to one of two arms: tebentafusp as
      monotherapy or observation. The primary endpoint of the trial is relapse-free survival (RFS), with secondary objectives of overall survival and safety and tolerability of tebentafusp. Exploratory objectives include the comparison of the
      health-related quality of life between the treatment arms and the evaluation of the role of circulating tumor DNA (ctDNA) as a biomarker for the presence of residual disease.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 6 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About Uveal Melanoma</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis
      is rare, and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.</div>
    <div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About Cutaneous Melanoma</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer-related
        mortality. The majority of patients with CM are diagnosed before metastasis but survival remains poor for the large proportion of patients with metastatic disease. Despite recent progress in advanced melanoma therapy, there is still an unmet need
        for new therapies that improve first-line response rates and duration of response as well as for patients who are refractory to first-line treatments.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a
      lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore&#8217;s ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for the
      treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">IMPORTANT SAFETY INFORMATION</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in
        patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.</font><font style="font-size: 10pt;"> Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea,
        vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are
        euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue
        KIMMTRAK depending on persistence and severity of CRS.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Skin Reactions</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions
      occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 7 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Elevated Liver Enzymes</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood
      bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Embryo-Fetal Toxicity</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during
      treatment with KIMMTRAK and 1 week after the last dose.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The most common adverse reactions (&#8805;30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal
      pain, edema, hypotension, dry skin, headache, and vomiting. The most common (&#8805;50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased
      phosphate.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About KIMMTRAKConnect</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore is committed to helping patients who need KIMMTRAK obtain access via our KIMMTRAKConnect program. The program provides services with dedicated nurse case
      managers who provide personalized support, including educational resources, financial assistance, and site of care coordination. To learn more, visit KIMMTRAKConnect.com or call 844-775-2273.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About Immunocore</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; Immune mobilizing
      monoclonal TCRs Against X disease &#8211; designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep
      pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs&#8203; in oncology, infectious diseases, and autoimmune diseases. The Company&#8217;s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the
      treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 8 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Forward Looking Statements</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words
      such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;aim&#8221;, &#8220;continue&#8221;, &#8220;target&#8221; and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking
      statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the Company&#8217;s ability to advance its clinical
      pipeline; the key growth areas for KIMMTRAK, including continued global expansion in mUM, the potential expansion into 2L+ advanced cutaneous melanoma, and potential expansion into adjuvant uveal melanoma; the commercial performance of KIMMTRAK; the
      potential benefits and advantages that KIMMTRAK will provide for patients; the potential of the Company&#8217;s bispecific TCR technology platform to offer a new approach for the treatment of certain chronic infections; expectations regarding the estimated
      size of the patient populations for the Company&#8217;s product candidates; expectations regarding the design, progress, timing, enrollment, randomization, scope, expansion, funding, and results of the Company&#8217;s existing and planned clinical trials, those
      of the Company&#8217;s collaboration partners or the combined clinical trials with the Company&#8217;s collaboration partners; the timing and sufficiency of clinical trial outcomes to support potential approval of any of the Company&#8217;s product candidates or those
      of, or combined with, its collaboration partners; the Company&#8217;s goals to develop and commercialize product candidates based on its KIMMTRAK platform alone or with collaboration partners; the expected submission of clinical trial applications; the
      potential regulatory approval, expected clinical benefits and availability of the Company&#8217;s product candidates; and the Company&#8217;s expectations regarding the payment of sales-related rebate accruals in the second half of 2025. Any forward-looking
      statements are based on management&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or
      implied by such forward-looking statements, many of which are beyond the Company&#8217;s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company&#8217;s business, financial position,
      strategy and anticipated milestones, including Immunocore&#8217;s ability to conduct ongoing and planned clinical trials; Immunocore&#8217;s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any
      future approved products; Immunocore&#8217;s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore&#8217;s ability and plans in continuing to establish and expand a commercial infrastructure and to
      successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore&#8217;s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the
      delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore&#8217;s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on
      a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and
      progress of clinical trials or future regulatory approval; Immunocore&#8217;s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and
      interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Immunocore&#8217;s ability to obtain, maintain and enforce intellectual property
      protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are
      described in greater detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the Securities and Exchange Commission, including Immunocore&#8217;s most recent Annual Report on Form 10-K for the year ended December 31, 2024 filed with the
      Securities and Exchange Commission on February 26, 2025, as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s subsequent filings with the SEC. All information in this press release is as of the date
      of the release, and the Company undertakes no duty to update this information, except as required by law.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 9 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Contact Information</div>
      <div style="text-align: justify; color: rgb(24, 87, 244); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">S&#233;bastien Desprez, VP Communications</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">T:<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>+44 (0) 7458030732</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">E: <font style="font-family: 'Times New Roman';"><u>sebastien.desprez@immunocore.com</u></font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Follow Immunocore on LinkedIn: @Immunocore</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investor Relations</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Clayton Robertson / Morgan Warenius</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">T: +1 (215) 384-4781</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">E: <font style="font-family: 'Times New Roman';"><u>ir@immunocore.com</u></font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman';"><u> <br>
        </u></font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 10 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Condensed Consolidated Statement of Operations</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Comparison of the Quarters and Year to Date Ended <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">June 30, 2025</font> and <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">2024</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands, except share and per share data)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zb4bd47dfad3047a89cfe587c2eb40d15" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Quarter Ended</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Year to Date</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"> June 30, </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">2025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June 30, </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June 30, </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">2025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June 30, </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Revenue from sale of therapies, net</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">97,964</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">75,347</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">191,845</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">145,689</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Collaboration revenue</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">53</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">213</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Total revenue</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">97,964</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">75,400</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">191,845</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">145,902</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Cost of revenue from sale of therapies</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,040</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,707</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,871</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,953</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Research and development expense</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(69,008</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(51,072</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(125,476</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(108,531</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Selling, general &amp; administrative expense</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(42,791</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(38,638</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(82,989</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(77,925</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Loss from operations</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(14,875</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(16,017</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(18,491</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(42,507</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Interest income</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,271</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">6,239</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">8,447</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">14,485</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Interest expense</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(3,045</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(4,277</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(6,070</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(7,516</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Foreign currency (loss) gain</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(738</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(508</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">2,342</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(2,914</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Other income, net</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,693</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,433</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">10,162</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,243</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Net income (loss) before income taxes</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(9,694</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(10,130</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(3,610</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(34,209</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Income tax expense</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(606</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,486</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,667</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,843</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Net income (loss)</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(10,300</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(11,616</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(5,277</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(36,052</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 52%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 52%;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Basic and diluted net loss per share</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(0.20</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(0.23</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(0.11</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">$</font></font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">(0.72</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">)</font></font></div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 52%; padding-bottom: 4px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">Basic and diluted weighted-average number of shares outstanding</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">50,294,205</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">50,014,086</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">50,191,018</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">49,944,767</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 11 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Condensed Consolidated Balance Sheets</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zc5194c39898b4f9e935e26a002c0dbc7" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"> June 30, 2025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">December 31, 2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">ASSETS</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Current assets</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Cash and cash equivalents</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">487,933</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">455,731</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Marketable securities</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">394,878</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">364,645</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Accounts receivable, net</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">69,761</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">63,009</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Prepaid expenses and other current assets</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">44,270</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">41,033</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Inventory, net</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,456</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,446</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Total current assets</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">1,002,298</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">929,864</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Property and equipment, net</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">9,548</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">10,092</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Operating lease right of use assets, net</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">39,428</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">37,643</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Deferred tax assets, net</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">14,077</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">14,790</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Other non-current assets</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">17,036</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">17,117</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Total assets</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">1,082,387</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">1,009,506</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Liabilities and shareholders&#8217; equity</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Current liabilities</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Accounts payable</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">23,856</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">25,100</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Accrued expenses and other current liabilities</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">143,785</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">185,534</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Deferred revenue, current</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">594</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';">&#8212;</font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Operating lease liabilities, current</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,843</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,547</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Total current liabilities</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">170,078</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">212,181</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Accrued expenses, non-current</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">83,960</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Deferred revenue, non-current</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,247</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,434</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Operating lease liabilities, non-current</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">42,561</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">40,162</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Interest-bearing loans and borrowings</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">392,060</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">391,013</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Total liabilities</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">693,906</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">648,790</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Shareholders' equity</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Ordinary shares</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">135</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">135</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Deferred shares</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Additional paid-in capital</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,215,997</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,190,104</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Accumulated deficit</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(801,038</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(795,761</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Accumulated other comprehensive loss</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(26,614</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(33,763</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Total shareholders' equity</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">388,481</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">360,716</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Total liabilities and shareholders' equity</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">1,082,387</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">1,009,506</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="text-align: justify; font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 12 of 13</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div><img src="image00002.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Summary Condensed Consolidated Statements of Cash Flows</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the Six Months Ended <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">June 30,</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z002aae9ce32449bba78101a57900f463" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"> 2025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Cash and cash equivalents at beginning of period</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">455,731</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">442,626</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Net cash provided by operating activities</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">26,399</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">18,885</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Net cash used in investing activities</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(20,712</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(350,761</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Net cash provided by financing activities</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">6,221</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">395,194</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Net foreign exchange difference on cash held</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">20,294</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(959</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Cash and cash equivalents at end of period (June 30)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">487,933</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">$</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">504,985</font></font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00004.jpg"></div>
                  </td>
                  <td style="width: 33.33%;">
                    <div>&#160;<img src="image00005.jpg"></div>
                  </td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><br>
                      </div>
                    </div>
                    <br>
                    <div style="text-align: right; color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 8pt;">Page 13 of 13</div>
                  </td>
                </tr>

            </table>
            <div> <br>
            </div>
            <div> <br>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-size: 10pt;"> </font>
  <div style="width: 100%;" class="BRPFPageFooter"> </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>imcr-20250807.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.7.1.5324 Broadridge-->
<xs:schema targetNamespace="http://immunocore.com./20250807" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:imcr="http://immunocore.com./20250807" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20250807_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20250807_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20250807_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://immunocore.com./role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xs:element name="OrdinaryShareNominalValue0002PerShareMember" id="imcr_OrdinaryShareNominalValue0002PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>imcr-20250807_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.7.1.5324 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://immunocore.com./role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="imcr-20250807.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://immunocore.com./role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine2" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine3" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="definition: EntityListingsLineItems to EntityAddressCountry" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="definition: EntityListingsLineItems to WrittenCommunications" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="definition: EntityListingsLineItems to SolicitingMaterial" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementTenderOffer" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="imcr-20250807.xsd#imcr_OrdinaryShareNominalValue0002PerShareMember" xlink:label="OrdinaryShareNominalValue0002PerShareMember" xlink:title="OrdinaryShareNominalValue0002PerShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="OrdinaryShareNominalValue0002PerShareMember" xlink:title="definition: ClassOfStockDomain to OrdinaryShareNominalValue0002PerShareMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>imcr-20250807_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.7.1.5324 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain" xml:lang="en-US" id="us-gaap_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable" xml:lang="en-US" id="dei_EntityListingsTable">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable" xlink:title="label: EntityListingsTable to dei_EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems" xml:lang="en-US" id="dei_EntityListingsLineItems">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="imcr-20250807.xsd#imcr_OrdinaryShareNominalValue0002PerShareMember" xlink:label="OrdinaryShareNominalValue0002PerShareMember" xlink:title="OrdinaryShareNominalValue0002PerShareMember" />
    <link:label xlink:type="resource" xlink:label="imcr_OrdinaryShareNominalValue0002PerShareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="imcr_OrdinaryShareNominalValue0002PerShareMember_lbl1" xml:lang="en-US" id="imcr_OrdinaryShareNominalValue0002PerShareMember_lbl1">Ordinary share, nominal value 0.002 per share* [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrdinaryShareNominalValue0002PerShareMember" xlink:to="imcr_OrdinaryShareNominalValue0002PerShareMember_lbl1" xlink:title="label: OrdinaryShareNominalValue0002PerShareMember to imcr_OrdinaryShareNominalValue0002PerShareMember_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>imcr-20250807_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.7.1.5324 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://immunocore.com./role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="imcr-20250807.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://immunocore.com./role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="imcr-20250807.xsd#imcr_OrdinaryShareNominalValue0002PerShareMember" xlink:label="OrdinaryShareNominalValue0002PerShareMember" xlink:title="OrdinaryShareNominalValue0002PerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="OrdinaryShareNominalValue0002PerShareMember" xlink:title="presentation: ClassOfStockDomain to OrdinaryShareNominalValue0002PerShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="presentation: EntityListingsLineItems to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="presentation: EntityListingsLineItems to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="presentation: EntityListingsLineItems to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  8 .<# 2(  A$! Q$!_\0
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/_P#LJ***V^H43+ZU4/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  W 'T# 2(  A$! Q$!_\0
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MN6\4FPGBVR7$,<D</F92,8)8[L#)Z?**9JNIZA;:EJUQ%>L(K.>WBCM2BE9
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MV2&ZG_M5II%)%Q\BIY1V@IVP<?-C&><FM^3Q1=64T2:C%:IYMFDR;)/O2LV
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,C HHJ6V]QI);'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image00005.jpg
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  Z )H# 2(  A$! Q$!_\0
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F%M$)O(4QP1LJ$1N&+$$GYF Q79T4_:2%R(.G2BBBLRPHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunocore Holdings plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">92 Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Abingdon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Oxfordshire<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 438600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value 0.002 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMCR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imcr_OrdinaryShareNominalValue0002PerShareMember', window );">Ordinary share, nominal value 0.002 per share* [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary share, nominal value 0.002 per share*<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imcr_OrdinaryShareNominalValue0002PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imcr_OrdinaryShareNominalValue0002PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20053240_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immunocore.com./role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20053240_8k.htm">ef20053240_8k.htm</File>
    <File>imcr-20250807.xsd</File>
    <File>imcr-20250807_def.xml</File>
    <File>imcr-20250807_lab.xml</File>
    <File>imcr-20250807_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20053240_8k.htm": {
   "nsprefix": "imcr",
   "nsuri": "http://immunocore.com./20250807",
   "dts": {
    "inline": {
     "local": [
      "ef20053240_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "imcr-20250807.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "imcr-20250807_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "imcr-20250807_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imcr-20250807_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 35,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 27
   },
   "report": {
    "R1": {
     "role": "http://immunocore.com./role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250807to20250807",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20053240_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250807to20250807",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20053240_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "imcr_OrdinaryShareNominalValue0002PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immunocore.com./20250807",
     "localname": "OrdinaryShareNominalValue0002PerShareMember",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary share, nominal value 0.002 per share* [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001140361-25-029350-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-029350-xbrl.zip
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M E9N COEB[NB*2\.:=Z.@/-)V9 ']H8E!7)$^9/BQ5D6]Z&:P0BE<<@I\D(
MJ)/T+!ZTD#&?6'8*&A]-$6X!8^]!N&A99_LDZ?)($6BYA<@PBR>ODKP5^4[:
M),GB'?//J./?YXO.[=DINKD]N3V[>>2V;\[:GZ\[MYVS&W1R<8K._FC_=G+Q
MZQEJ7YZ?=VYN.I<7#T,0KB/H]Y.;WSH7O]Y>7AR@TT:[ =Z7:;BS1!P?I0/
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M_Y)?@(,+ (H(E-\? PNFP:W\\L!X\VOZ#@YSX,Q3%N%Q#R0 D@L9>6'"G$D
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M0#& F5M/:QS^_%LGO I@&3C_^(ZQ&V*K,)^%*PB':H3Y>_ 5<>BGR&?XR%@
M1SI3SN[\F5Z ?KH\\DB6X4Z\*ZQ4)EHZ^G!+"^/+"!V//=Y:6%A:?=746PP+
MAI];4^2C<E\\#42[I^,/'3G)EJR2R,NA<S,Q;)K2=ODQA.4!!5]R&:PUKWX(
MUZ8,"SUQ7_Y8[;H7C#U?5D?$684RR:.8UZV6J?AS*C(W)J'OUB39\#P:D'"
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MGHK ;^2YH5.A:<<'/$ 9JT?R C$8;(3588!X2&6;LT7.=AOS+OS"9T,.*9F
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M7LSNM3J%ICF%:H)BDU'$H$+ J"<PT3V6$^F=Q$@*/=A1DD&.BMW=8E$7#<C
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M;#A?3#0,%)F".H3D-6 9$WGR<AM"E9_4V!345T467T74RAS\$X.1W\W!W]5
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MO0!%GM!X( S+\[(TJVPM3OLD33>-=H"LV&<8\V'D!G .5B$]8(Z&V(?-&$<
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M-7OS]XW_*YVZ*:G^]<SL=U!+ P04    "  9/0=;KU=R @$'  !\30  %0
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M&C_X-Z#M6O@/_HUA'_\'4$L! A0#%     @ &3T'6Y!N*AET%   4(8  !$
M             ( !     &5F,C P-3,R-#!?.&LN:'1M4$L! A0#%     @
M&3T'6[HQ!>Z41@  7;0# !4              ( !HQ0  &5F,C P-3,R-#!?
M97@Y.2TQ+FAT;5!+ 0(4 Q0    ( !D]!UO*Q[0!P@,   T1   1
M      "  6I;  !I;6-R+3(P,C4P.# W+GAS9%!+ 0(4 Q0    ( !D]!UN7
M;>% ]P8  /%$   5              "  5M?  !I;6-R+3(P,C4P.# W7V1E
M9BYX;6Q02P$"% ,4    "  9/0=;0=XCNC(*  #%9P  %0
M@ &%9@  :6UC<BTR,#(U,#@P-U]L86(N>&UL4$L! A0#%     @ &3T'6Z]7
M<@(!!P  ?$T  !4              ( !ZG   &EM8W(M,C R-3 X,#=?<')E
:+GAM;%!+!08     !@ & (H!   >>      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ef20053240_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:imcr="http://immunocore.com./20250807"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imcr-20250807.xsd" xlink:type="simple"/>
    <context id="c20250807to20250807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-08-07</endDate>
        </period>
    </context>
    <context id="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imcr:OrdinaryShareNominalValue0002PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-08-07</endDate>
        </period>
    </context>
    <context id="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-08-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20250807to20250807"
      id="Fact_b3355e7afd134da98ef2d366017b2bdd">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20250807to20250807"
      id="Fact_2bb2ff8a1d514e0f92155a8af4dd2855">0001671927</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250807to20250807"
      id="Fact_ac7c4eab29c54bb6b88e909e2360e22b">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:Security12bTitle
      contextRef="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember"
      id="Fact_d07e454d9f4444e1ad37e53e75c19776">Ordinary share, nominal value 0.002 per share*</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_5af8aa2b527b407485ad42ded70d51ee">American Depositary Shares, each representing one ordinary share, nominal value 0.002 per share</dei:Security12bTitle>
    <dei:DocumentType
      contextRef="c20250807to20250807"
      id="Fact_e14cb2c6bd1f4d33a1db6fca8b703a2d">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20250807to20250807"
      id="Fact_dceaf50e2d524f0fae6e5b59b7205fc4">2025-08-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20250807to20250807"
      id="Fact_e55dc27569a8495e97786f825e9188e2">Immunocore Holdings plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250807to20250807"
      id="Fact_06998ea623be432aad71bf315b91f67d">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20250807to20250807"
      id="Fact_7dce5ffc0f264b20abdca32b4a45a20f">001-39992</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250807to20250807"
      id="Fact_46e5c566e8eb405abf21725748935d1d">92 Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20250807to20250807"
      id="Fact_95f617049bc942d593fd1b5f13a61778">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="c20250807to20250807"
      id="Fact_2b35e479375a46ef8796d244fc39beff">Abingdon</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="c20250807to20250807"
      id="Fact_bfeab88c8d1646f09d58409c722f187c">Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="c20250807to20250807"
      id="Fact_08740d26ec02473fa7b3e6b37c070ddd">GB</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250807to20250807"
      id="Fact_4721703b195b4a7a98652eb8f2ba63f2">OX14 4RY</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250807to20250807"
      id="Fact_5fea8556eec74b66a8d562928004531a">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250807to20250807"
      id="Fact_957c021778bb4b7a964ddb527ceab834">1235 438600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20250807to20250807"
      id="Fact_15bef933971a4270a276eed798d5ad16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20250807to20250807"
      id="Fact_39c6a35b10dc4b4db335ad40aa4e993f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20250807to20250807"
      id="Fact_d1f93730d23d4d84931c37f4ffb1482b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20250807to20250807"
      id="Fact_64c319898d924379b11fc0078e2c2447">false</dei:PreCommencementIssuerTenderOffer>
    <dei:TradingSymbol
      contextRef="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_2f4aa51e7378452fb34d506535263427">IMCR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250807to20250807_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_1f406a9fd194457b83c718f7976016b3">NASDAQ</dei:SecurityExchangeName>
    <dei:TradingSymbol
      contextRef="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember"
      id="Fact_4441c2a305004faa95535fac876dd8b9">*</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250807to20250807_StatementClassOfStockAxis_OrdinaryShareNominalValue0002PerShareMember"
      id="Fact_b0a2ac7baae34f33a1f9ecb102667551">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250807to20250807"
      id="Fact_d9646ea31d2f47d493701a56d2ced180">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
